|
|
|
| Study development of Peroxiredoxins in tumors |
| ZENG Wei1，2 XIAO Tao1 CAI Anlie2 |
1.Department of Orthopedics, the Second Xiangya Hospital of Central South University, Hu′nan Province, Changsha 410011, China;
2.Department of Orthopedics, Affiliated Zhuzhou Hospital of Central South University Xiangya Medical College, Central Hospital of Zhuzhou City, Hu′nan Province, Zhuzhou 412000, China |
|
|
|
Abstract Peroxiredoxins (Prdx) is one kind of antioxidant enzymes in cells which can catalysis oxidation-reduction reactions to balance the level of hydrogen peroxide. They can also act as an important regulator in oxidation-reduction signal pathway, which is important for signal transduction and metabolism in cells. Many studies have showed that Prdx family plays different roles in tumors. Because of the change oftumor gene groups, their expressions changed, with the change of oxidation-reduction signal pathway. These changes lead to the influence of biological actions of tumors, offering new ideas of treatment of tumors. Therefore, we make a short conclusion of study about Prdx in tumors, in order to find a new way to treat tumors.
|
|
|
|
|
|
[1] Andrew KP. A primer on Peroxiredoxin biochemistry [J]. Free Radic Biol Med，2015，80（4）：183-190.
[2] Ritter J，Bielack SS. Osteosarcoma [J]. Ann Oncol，2010， 21（1）： 320-325.
[3] Isakoff MS，Bielack SS，Meltzer P. Osteosarcoma：current treatment and a collaborative pathway to success [J]. J Clin Oncol，2015，33（10）：3029-3035.
[4] Knoops B，Argyropoulou V，Becker S，et al. Multiple roles of peroxiredoxins in inflammation [J]. Mol Cells，2016，39（1）：60-64.
[5] Ren HY，Sun LL，Li HY. Prognostic significance of serum alkaline phosphatase level in osteosarcoma：a meta-analysis of published data [J]. Biomed Res Int，2015，356（5）：160-185.
[6] Zhang Y，Zhang L，Zhang G，et al. Osteosarcoma metastasis：prospective role of ezrin [J]. Tumour Biol，2015，35（5）：5055-5059.
[7] Scott MC，Sarver AL，Tomiyasu H，et al. Aberrant retinoblastoma（RB）-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma [J]. J Biol Chem，2015，290（68）：28070-28083.
[8] Del MS，Husanie H，Lancu O，et al. WWOX and p53 dysregulation synergize to drive the development of osteosarcoma [J]. Cancer Res，2016，76（8）：6107-6117.
[9] Hofmann B，Hecht HJ，Flohe L. Peroxiredoxins [J]. Biol Chem，2002，383（20）：347-364.
[10] Bryk R，Griffin P，Nathan C. Peroxynitritereductase activity of bacterial peroxiredoxins [J]. Nature，2000，407（9）：211-215.
[11] Hoshino I，Matsubara H，Hanari N，et al. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells [J]. Clin Cancer Res，2005，11（2）：7945-7952.
[12] Riddell JR，Bshara W，Moser MT，et al. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature [J]. Cancer Res，2011，71（6）：1637-1646.
[13] Yanagawa T，Lwasa S，Lshii T，et al. Peroxiredoxin 1 expression in oral cancer：a potential new tumor marker [J]. Cancer Lett，2000，156（23）：27-35.
[14] Chang JW，Lee SH，Jeong JY，et al. Peroxiredoxin-1 is an autoimmunogenic tumor antigen in non-small cell lung cancer [J]. FEBS Lett，2005，579（56）：2873-2877.
[15] McShane LM，Altman DG，Sauerbrei W，et al. Reporting recommendations for tumor marker prognostic studies（REMARK） [J]. J Natl Cancer Inst，2005，97（8）：1180-1184.
[16] Su S，Liu Q，Chen J，et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis [J]. Cancer Cell，2014，25（5）：605-620.
[17] Ding CB，Fan XB，Wu GQ. Peroxiredoxin 1—an antioxidant enzyme in cancer [J]. J Cell Mol Med，2017，21（1）：193-202.
[18] Mark B，Karina M. Peroxiredoxins and the regulation of cell death [J]. Mol Cells，2016，39（1）：72-76.
[19] Chang RM，Yang H，Fang F，et al. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase [J]. Hepatology，2014，60（5）：1251-1263.
[20] Pullar CE，Chen J，Lsseroff RR. PP2A activation by beta2-adrenergic receptor agonists：novel regulatory mechanism of keratinocyte migration [J]. J Biol Chem，2003， 278（80）： 22555-22562.
[21] Fang F，Chang RM，Yu L，et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma [J]. J Hepatol，2015，63（9）：874-885.
[22] Gong F，Hou G，Liu H. Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma [J]. Med Oncol，2015，32（6）：455-459.
[23] Heather R，Elizabeth A. Peroxiredoxins in regulation of MAPK signalling pathways；sensors and barriers to signal transduction [J]. Mol Cells，2016，39（1）：40-45.
[24] Mishra M，Jiang H，Wu L，et al. The sulfiredoxin-peroxiredoxin （Srx-Prx） axis in cell signal transduction and cancer development [J]. Cancer Lett，2015，366（2）：150-159.
[25] Perkins A，Nelson K，Parsonage D，et al. Peroxiredoxins：guardians against oxidative stress and modulators of peroxide signaling [J]. Trends Biochem Sci，2015，40（8）：435-445.
[26] Ferrari S，BertoniF，Mercuri M，et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity：an analysis of 300 patients treated at the Rizzoli Institute[J]. Ann Oncol，2001，12（5）：1145-1150.
[27] Netto L，Antunes F. The roles of Peroxiredoxin and thioredoxin in hydrogen peroxide sensing and in signal transduction [J]. Mol Cells，2016，39（1）：65-71.
[28] Lessard J，Wu JI，Ranish JA，et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development [J]. Neuron，2007，55（8）：201-215. |
|
|
|
